Dimitrios Zardavas

Dimitrios Zardavas

UNVERIFIED PROFILE

Are you Dimitrios Zardavas?   Register this Author

Register author
Dimitrios Zardavas

Dimitrios Zardavas

Publications by authors named "Dimitrios Zardavas"

Are you Dimitrios Zardavas?   Register this Author

39Publications

1050Reads

49Profile Views

Progress in adjuvant systemic therapy for breast cancer.

Nat Rev Clin Oncol 2019 01;16(1):27-44

Research Department, Institut Jules Bordet, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0089-9DOI Listing
January 2019

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

CDK4/6 blockade in breast cancer: current experience and future perspectives.

Expert Opin Investig Drugs 2017 Dec 23;26(12):1357-1372. Epub 2017 Oct 23.

c Medical Department , European Organization for Research and Treatment of Cancer (EORTC) , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1389896DOI Listing
December 2017

New agents for endocrine resistance in breast cancer.

Breast 2017 Aug 24;34:1-11. Epub 2017 Apr 24.

Clinique d'Oncologie Médicale, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776173043
Publisher Site
http://dx.doi.org/10.1016/j.breast.2017.04.007DOI Listing
August 2017

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

N Engl J Med 2017 Jul 5;377(2):122-131. Epub 2017 Jun 5.

From the German Breast Group, Neu-Isenburg, Germany (G.M.); Frontier Science (Scotland), Kincraig, United Kingdom (M. Procter); the Breast European Adjuvant Study Team (BrEAST) Data Center (E.A., N.R.), the Breast International Group (D.Z., A.A.), and Institut Jules Bordet, Université Libre de Bruxelles (M. Piccart) - all in Brussels; Roche Pharma (M.B., E.C., A.K.) and the Department of Cardiology, Cardio-Oncology, Bern University Hospital (T.S.) - both in Bern, Switzerland; the Department of Pathology, European Institute of Oncology, University of Milan, Milan (G.V.); the National Institute of Oncology, Budapest, Hungary (I.L.); Centre François Baclesse, Caen, France (C.L.); the Sarah Cannon Research Institute and Tennessee Oncology, Nashville (D.A.Y.); Instituto Nacional de Câncer, Rio de Janeiro (J. Bines); Dana-Farber Cancer Institute, Harvard Medical School, Harvard T. H. Chan School of Public Health, and Frontier Science and Technology Research Foundation - all in Boston (R.D.G.); and the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (J. Baselga).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1703643DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020PMC
July 2017

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.

Clin Cancer Res 2017 Jun 9;23(11):2702-2712. Epub 2016 Nov 9.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brusells, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0979DOI Listing
June 2017

The past and future of breast cancer treatment-from the papyrus to individualised treatment approaches.

Ecancermedicalscience 2017 8;11:746. Epub 2017 Jun 8.

Breast International Group (BIG), Boulevard de Waterloo 76, Brussels 1000, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2017.746DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481194PMC
June 2017

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.

J Clin Oncol 2017 Mar 23;35(8):878-884. Epub 2016 Oct 23.

Dimitrios Zardavas, Breast International Group; Martine J. Piccart-Gebhart and Evandro de Azambuja, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Thomas M. Suter, Bern University Hospital, Bern; Jutta Steinseifer, Johannes Noe, Sabine Lauer, and Nedal Al-Sakaff, F. Hoffmann-La Roche, Basel, Switzerland; and Dirk J. Van Veldhuisen, University Medical Center Groningen, University of Groningen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7916DOI Listing
March 2017

Targeted adjuvant therapy in breast cancer.

Expert Rev Anticancer Ther 2016 Dec 27;16(12):1263-1275. Epub 2016 Oct 27.

c Institut Jules Bordet, Université Libre de Bruxelles , Brussels , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2016.1247698DOI Listing
December 2016

Endocrine treatment in breast cancer: Cure, resistance and beyond.

Cancer Treat Rev 2016 Nov 7;50:68-81. Epub 2016 Sep 7.

Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.08.008DOI Listing
November 2016

New generation of breast cancer clinical trials implementing molecular profiling.

Cancer Biol Med 2016 Jun;13(2):226-35

Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 100, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20892/j.issn.2095-3941.2015.0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944544PMC
June 2016

Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer.

Am Soc Clin Oncol Educ Book 2015 :e183-90

From the Breast International Group, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e183DOI Listing
February 2016

Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .

Am Soc Clin Oncol Educ Book 2013

From the Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom; and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e2DOI Listing
November 2015

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

Breast 2015 Nov 5;24 Suppl 2:S143-8. Epub 2015 Aug 5.

Institut Jules Bordet, Université Libre des Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.07.034DOI Listing
November 2015

Neoadjuvant therapy for breast cancer.

Annu Rev Med 2015 27;66:31-48. Epub 2014 Oct 27.

Breast International Group Headquarters (BIG-aisbl), Brussels 1000, Belgium; email: ,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-051413-024741DOI Listing
September 2015

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

J Clin Oncol 2015 Aug 22;33(24):2600-8. Epub 2015 Jun 22.

Ciara C. O'Sullivan and Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Ian Bradbury, Christine Campbell, and Eileen Holmes, Frontier Science, Inverness-shire, Scotland; Marc Spielmann and Suzette Delaloge, Institut de Cancérologie Gustave Roussy, Villejuif, France; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Joseph P. Costantino and Priya Rastogi, University of Pittsburgh, Pittsburgh, PA; Dimitrios Zardavas, Breast International Group; Karla V. Ballman, Mayo Clinic, Rochester, MN; Evandro de Azambuja and Martine Piccart-Gebhart, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium; and Richard D. Gelber, Harvard Medical School, Harvard T.H. Chan School of Public Health, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534523PMC
http://dx.doi.org/10.1200/JCO.2015.60.8620DOI Listing
August 2015

Clinical management of breast cancer heterogeneity.

Nat Rev Clin Oncol 2015 Jul 21;12(7):381-94. Epub 2015 Apr 21.

Jules Bordet Institute, Boulevard de Waterloo 121, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2015.73DOI Listing
July 2015

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.

Eur J Cancer 2014 Dec 19;50(18):3089-97. Epub 2014 Oct 19.

Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.09.011DOI Listing
December 2014

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

J Clin Oncol 2014 Sep 21;32(25):2794-803. Epub 2014 Jul 21.

Felipe Ades, Lina Pugliano, Debora Fumagalli, Evandro de Azambuja, Christos Sotiriou, and Martine Piccart, Institut Jules Bordet, Université Libre de Bruxelles; Dimitrios Zardavas, Breast International Group, Brussels, Belgium; Ivana Bozovic-Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; and Giuseppe Viale, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1870DOI Listing
September 2014

Cardiotoxicity of systemic agents used in breast cancer.

Breast 2014 Aug 1;23(4):317-28. Epub 2014 May 1.

Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.04.002DOI Listing
August 2014

Anticancer drug development: moving away from the old habits.

Curr Opin Oncol 2014 May;26(3):334-9

aMedical Oncology Clinic bBreast International Group Headquarters (BIG-aisbl), Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000076DOI Listing
May 2014

Clinical practice-changing trials: the HERA study paradigm.

Expert Rev Anticancer Ther 2013 Nov 21;13(11):1249-56. Epub 2013 Oct 21.

Medical Oncology Department, Institut Jules Bordet, Br.E.A.S.T. Data Centre Brussels, Blvd de Waterloo, 121 (7th Floor), 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.2013.848168DOI Listing
November 2013

Personalized therapy for breast cancer: a dream or a reality?

Future Oncol 2013 Aug;9(8):1105-19

Institut Jules Bordet, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.13.57DOI Listing
August 2013

Emerging targeted agents in metastatic breast cancer.

Nat Rev Clin Oncol 2013 Apr 5;10(4):191-210. Epub 2013 Mar 5.

Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2013.29DOI Listing
April 2013